SG11202111154WA - Ionizable amine lipids and lipid nanoparticles - Google Patents
Ionizable amine lipids and lipid nanoparticlesInfo
- Publication number
- SG11202111154WA SG11202111154WA SG11202111154WA SG11202111154WA SG11202111154WA SG 11202111154W A SG11202111154W A SG 11202111154WA SG 11202111154W A SG11202111154W A SG 11202111154WA SG 11202111154W A SG11202111154W A SG 11202111154WA SG 11202111154W A SG11202111154W A SG 11202111154WA
- Authority
- SG
- Singapore
- Prior art keywords
- dod
- mmm
- hhh hhh
- eee
- odd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838551P | 2019-04-25 | 2019-04-25 | |
| US201962843854P | 2019-05-06 | 2019-05-06 | |
| PCT/US2020/029812 WO2020219876A1 (en) | 2019-04-25 | 2020-04-24 | Ionizable amine lipids and lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111154WA true SG11202111154WA (en) | 2021-11-29 |
Family
ID=70805203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111154WA SG11202111154WA (en) | 2019-04-25 | 2020-04-24 | Ionizable amine lipids and lipid nanoparticles |
Country Status (15)
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600208B2 (ja) * | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| CN115175894B (zh) * | 2020-01-09 | 2024-09-06 | 盖德治疗有限责任公司 | 纳米材料 |
| KR20230017783A (ko) | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| EP4158032A2 (en) | 2020-05-29 | 2023-04-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and methods relating thereto |
| US20230203510A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
| EP4182296A1 (en) * | 2020-07-17 | 2023-05-24 | Sanofi Pasteur | Cleavable lipidic compounds, compositions containing thereof, and uses thereof |
| IL300947A (en) | 2020-09-03 | 2023-04-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| WO2022060871A1 (en) * | 2020-09-15 | 2022-03-24 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| EP4259792A1 (en) | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| CN116887841A (zh) * | 2020-12-21 | 2023-10-13 | 比姆医疗股份有限公司 | 包括酯连接缩醛的纳米材料 |
| EP4262817A4 (en) * | 2020-12-21 | 2025-03-12 | Beam Therapeutics Inc. | NANOMATERIALS WITH ACETALS |
| JP2024508347A (ja) * | 2020-12-21 | 2024-02-27 | ビーム セラピューティクス インク. | エステル結合アセタールを含むナノ材料 |
| KR20230135585A (ko) | 2020-12-23 | 2023-09-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 trem의 조성물 및 이의 용도 |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| EP4281080A4 (en) * | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3216873A1 (en) * | 2021-04-17 | 2022-10-22 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP4322920A1 (en) | 2021-04-17 | 2024-02-21 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| US20240300977A1 (en) | 2021-04-17 | 2024-09-12 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
| PL4332086T3 (pl) * | 2021-04-28 | 2026-06-15 | Fujifilm Corporation | Związek lub jego sól, cząstki lipidowe, i kompozycja farmaceutyczna |
| TW202317764A (zh) | 2021-06-10 | 2023-05-01 | 美商英特利亞醫療公司 | 用於基因編輯之包含內部連接子之經修飾引導rna |
| CA3226487A1 (en) * | 2021-07-12 | 2023-02-23 | University Of Cincinnati | Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same |
| WO2023023410A2 (en) * | 2021-07-12 | 2023-02-23 | University Of Cincinnati | Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same |
| WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| EP4380576A4 (en) * | 2021-08-03 | 2026-04-29 | Verve Therapeutics Inc | RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS |
| WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| AR127073A1 (es) | 2021-09-17 | 2023-12-13 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| CN113773216B (zh) * | 2021-09-30 | 2022-12-27 | 贵州大学 | 一种长链脂肪酸甘油醇类化合物Rubracin A、制备方法及其应用 |
| JP7883580B2 (ja) * | 2021-10-08 | 2026-07-01 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
| EP4419706A1 (en) | 2021-10-18 | 2024-08-28 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| KR20240090727A (ko) | 2021-10-22 | 2024-06-21 | 세일 바이오메디슨스, 인크. | Mrna 백신 조성물 |
| EP4426822A2 (en) | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| US20250002941A1 (en) | 2021-11-23 | 2025-01-02 | Sail Biomedicines, Inc. | A bacteria-derived lipid composition and use thereof |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| WO2023096990A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
| MX2024006407A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones de inmunogenos del virus varicela-zoster y sus usos. |
| CN118510896A (zh) | 2021-12-17 | 2024-08-16 | 旗舰创业创新六公司 | 用于在变性条件下富集环状rna的方法 |
| WO2023121965A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterial comprising diamines |
| CA3241488A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine lipids and lipid nanoparticles |
| EP4452239A1 (en) | 2021-12-20 | 2024-10-30 | Sail Biomedicines, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
| WO2023121964A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| EP4453201A1 (en) | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| AU2022420620A1 (en) | 2021-12-23 | 2024-07-04 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| JP2025502599A (ja) * | 2021-12-23 | 2025-01-28 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
| CA3242974A1 (en) | 2021-12-29 | 2023-07-06 | Shanghai Senhui Medicine Co., Ltd. | LIPID AND COMPOSITION USED FOR ADMINISTRATION |
| JP2025504430A (ja) * | 2022-01-17 | 2025-02-12 | サノフイ | 脂質化合物及びその使用 |
| CN114213347B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN114213346B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| US20250250227A1 (en) * | 2022-02-28 | 2025-08-07 | Shenzhen Shenxin Biotechnology Co., Ltd. | Amino lipid compound, preparation method therefor, composition thereof and use thereof |
| CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
| CA3245624A1 (en) | 2022-03-25 | 2023-09-28 | Sail Biomedicines, Inc. | NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE |
| CN116924923A (zh) * | 2022-04-02 | 2023-10-24 | 科镁信(上海)生物医药科技有限公司 | 阳离子脂质、脂质体及用途 |
| EP4504694A4 (en) * | 2022-04-05 | 2026-07-15 | Capstan Therapeutics Inc | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES |
| JP2025511756A (ja) | 2022-04-08 | 2025-04-16 | フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー | ワクチン及び関連する方法 |
| EP4519243A4 (en) * | 2022-05-04 | 2026-04-22 | Univ Pennsylvania | Siloxane-based lipids, lipid nanoparticle compositions comprising them, and their methods of use for targeted administration |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| JP2025516638A (ja) | 2022-05-13 | 2025-05-30 | フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー | 二本鎖dna組成物及び関連する方法 |
| WO2023230601A1 (en) | 2022-05-27 | 2023-11-30 | Beam Therapeutics Inc. | Identification of nanoparticles for preferential tissue or cell targeting |
| US20250325492A1 (en) * | 2022-06-03 | 2025-10-23 | University Of Cincinnati | Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same |
| CN119384498A (zh) | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| EP4544043A1 (en) | 2022-06-22 | 2025-04-30 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| KR20250042143A (ko) * | 2022-06-23 | 2025-03-26 | 턴 바이오테크놀로지스 인코포레이티드 | 지질 구조 및 이를 포함하는 조성물 |
| WO2024012270A1 (zh) * | 2022-07-11 | 2024-01-18 | 传信生物医药(苏州)有限公司 | 用于核酸的器官特异性递送组合物 |
| CA3262260A1 (en) | 2022-07-15 | 2025-06-12 | Shenzhen Shenxin Biotechnology Co., Ltd. | AMINO-LIPID COMPOUND, ITS PREPARATION PROCESS, ASSOCIATED COMPOSITION AND ASSOCIATED APPLICATION |
| CN115043790B (zh) * | 2022-07-18 | 2023-09-26 | 贵州大学 | 一种对称杂环化合物、制备方法及其应用 |
| EP4540222A1 (en) | 2022-07-20 | 2025-04-23 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| CN119677852A (zh) | 2022-07-29 | 2025-03-21 | 麻省理工学院 | 抑制信号调节蛋白α(SIRPα)基因表达的组合物和方法 |
| US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| EP4569112A1 (en) | 2022-08-12 | 2025-06-18 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| EP4581012A2 (en) | 2022-08-31 | 2025-07-09 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| KR20250110209A (ko) | 2022-09-23 | 2025-07-18 | 엔크로마 바이오, 인크. | Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024078614A1 (zh) * | 2022-10-13 | 2024-04-18 | 深圳深信生物科技有限公司 | 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒 |
| EP4612296A1 (en) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| EP4615424A1 (en) | 2022-11-10 | 2025-09-17 | Sail Biomedicines, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| AU2023379598A1 (en) * | 2022-11-16 | 2025-05-08 | Seawolf Therapeutics, Inc. | Ionizable lipids and lipid nanoparticle compositions for the delivery of nucleic acids |
| WO2024128525A1 (ko) * | 2022-12-12 | 2024-06-20 | 한국과학기술연구원 | 신규한 지질 화합물 및 이를 포함하는 지질 나노입자 조성물 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 用於將治療劑遞送至骨之組成物和方法 |
| EP4638783A2 (en) | 2022-12-22 | 2025-10-29 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| CN120418427A (zh) | 2022-12-23 | 2025-08-01 | 因特利亚治疗公司 | 用于基因组编辑的系统和方法 |
| JP2025534494A (ja) * | 2022-12-23 | 2025-10-15 | グリーン・クロス・コーポレイション | イオン化可能な脂質及びその使用 |
| EP4648794A2 (en) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccines and related methods |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| JP2026503676A (ja) | 2023-01-27 | 2026-01-29 | セイル バイオメディシンズ インコーポレイテッド | 修飾脂質組成物およびその使用 |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 免疫調節組合物及相關方法 |
| US20240293318A1 (en) | 2023-02-13 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
| TW202446956A (zh) | 2023-02-17 | 2024-12-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 包含經修飾的胞嘧啶的dna組成物 |
| KR20250151437A (ko) | 2023-02-17 | 2025-10-21 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 변형된 우라실을 포함하는 dna 조성물 |
| EP4680750A1 (en) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions comprising polyribonucleotides and uses thereof |
| EP4680276A1 (en) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
| WO2024199282A1 (zh) * | 2023-03-28 | 2024-10-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| EP4692059A1 (en) * | 2023-03-29 | 2026-02-11 | Tohoku University | Cationic lipid having disulfide bond |
| WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| AU2024255972A1 (en) | 2023-04-12 | 2025-10-23 | Flagship Pioneering Innovations Vi, Llc | Modified trems, compositions, and related methods thereof |
| WO2024220752A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Rna therapeutic compositions |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| EP4698150A1 (en) | 2023-04-19 | 2026-02-25 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024229032A2 (en) * | 2023-05-01 | 2024-11-07 | Factor Bioscience Inc. | Multivalent ionizable lipid delivery systems |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ,インコーポレーテッド | Hbv遺伝子発現のエピジェネティック調節のための組成物および方法 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| EP4736848A1 (en) | 2023-06-28 | 2026-05-06 | Shanghai Regenelead Therapies Co., Ltd. | Pharmaceutical composition containing cationic lipid and use thereof |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| CN117024323A (zh) * | 2023-07-21 | 2023-11-10 | 中国科学院基础医学与肿瘤研究所(筹) | 一种可降解、可电离的阳离子脂材及其应用 |
| KR20260044217A (ko) | 2023-07-25 | 2026-04-01 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Cas 엔도뉴클레아제 및 관련 방법 |
| EP4762030A1 (en) * | 2023-08-16 | 2026-06-24 | Beam Therapeutics Inc. | Ionizable lipids with branched head groups |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025045247A1 (en) * | 2023-08-31 | 2025-03-06 | Geneditbio Limited | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| KR20260094503A (ko) * | 2023-09-13 | 2026-06-22 | 테세라 테라퓨틱스, 인크. | 치료용 페이로드를 세포에 전달하기 위한 지질 나노입자 |
| IL327035A (en) | 2023-09-18 | 2026-05-01 | Flagship Pioneering Innovations Vii Llc | Ionizable lipidoid compositions and their medical uses |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| US20250127728A1 (en) * | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| KR20260113064A (ko) | 2023-11-14 | 2026-07-21 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 이온화 가능한 리피도이드 조성물 및 이의 치료적 용도 |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025106930A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof |
| WO2025111454A1 (en) * | 2023-11-21 | 2025-05-30 | University Of Cincinnati | Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2025193861A2 (en) * | 2024-03-12 | 2025-09-18 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025212932A1 (en) * | 2024-04-03 | 2025-10-09 | Intellia Therapeutics, Inc. | Methods of synthesizing amine lipids |
| WO2025217129A1 (en) * | 2024-04-08 | 2025-10-16 | Popvax Private Limited | Novel lipids for delivery of nucleic acid therapeutics |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025217452A1 (en) * | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202613158A (zh) | 2024-05-16 | 2026-04-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| WO2025250729A1 (en) * | 2024-05-29 | 2025-12-04 | Liberate Bio, Inc. | Lipid compounds, compositions, and uses thereof |
| WO2025250730A1 (en) * | 2024-05-29 | 2025-12-04 | Liberate Bio, Inc. | Lipid compounds, compositions, and uses thereof |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026029040A1 (ja) * | 2024-07-29 | 2026-02-05 | 日油株式会社 | アミノ脂質及び脂質ナノ粒子 |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026035680A1 (en) | 2024-08-06 | 2026-02-12 | Kernal Biologics, Inc. | Compositions and methods for delivery of agents |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2026064313A1 (en) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Rna compositions and related methods |
| WO2026085300A1 (en) | 2024-10-16 | 2026-04-23 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
| WO2026097018A1 (en) | 2024-11-04 | 2026-05-07 | Intellia Therapeutics, Inc. | Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers |
| WO2026102108A1 (en) | 2024-11-07 | 2026-05-15 | Flagship Pioneering Innovations Vii, Llc | Dna production methods |
| WO2026122747A2 (en) | 2024-12-05 | 2026-06-11 | Flagship Pioneering Innovations Vii, Llc | Novel immunomodulatory proteins and related methods |
| WO2026122996A1 (en) * | 2024-12-06 | 2026-06-11 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| WO2026136246A1 (en) * | 2024-12-16 | 2026-06-25 | Acuitas Therapeutics, Inc. | Novel lipid compounds and methods of their use |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
| WO2026151879A1 (en) | 2025-01-10 | 2026-07-16 | Flagship Pioneering Innovations Vii, Llc | Vaccine compositions and methods |
| WO2026152023A1 (en) | 2025-01-10 | 2026-07-16 | Sail Biomedicines, Inc. | Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides |
| WO2026152164A1 (en) | 2025-01-13 | 2026-07-16 | Sail Biomedicines, Inc. | Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo |
| WO2026161677A1 (en) | 2025-01-24 | 2026-07-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
| WO2026163162A1 (en) | 2025-01-31 | 2026-08-06 | Intellia Therapeutics, Inc. | Enhanced cas9 variants and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6044994A (en) * | 1993-02-19 | 1994-09-14 | Nippon Shinyaku Co. Ltd. | Glycerol derivative, device and pharmaceutical composition |
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| EP3100718B1 (en) * | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| AU2012325997C1 (en) * | 2011-10-18 | 2018-07-05 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| DE21212055T1 (de) * | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| JP2017500865A (ja) * | 2013-12-19 | 2017-01-12 | ノバルティス アーゲー | レプチンmRNAの組成物および製剤 |
| US10059655B2 (en) * | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| HUE067372T2 (hu) * | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| HRP20220156T1 (hr) * | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| ES3030658T3 (en) * | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| BR112019025104A2 (pt) * | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição |
| KR102676927B1 (ko) * | 2017-06-15 | 2024-06-24 | 국립대학법인 홋가이도 다이가쿠 | siRNA 세포 내 송달을 위한 지질막 구조체 |
| ES2964547T3 (es) * | 2018-06-08 | 2024-04-08 | Fujifilm Corp | Compuesto, sal del mismo y partículas lipídicas |
| ES2951836T3 (es) * | 2018-10-01 | 2023-10-25 | Alnylam Pharmaceuticals Inc | Lípidos biodegradables para el suministro de agentes activos |
| MX2021003455A (es) * | 2018-10-02 | 2021-09-21 | Intellia Therapeutics Inc | Lípidos con amina ionizables. |
| CN119285480A (zh) * | 2018-12-05 | 2025-01-10 | 英特利亚治疗股份有限公司 | 改性的胺脂质 |
-
2020
- 2020-04-24 WO PCT/US2020/029812 patent/WO2020219876A1/en not_active Ceased
- 2020-04-24 BR BR112021021313A patent/BR112021021313A2/pt not_active IP Right Cessation
- 2020-04-24 CN CN202080030542.7A patent/CN114127044A/zh active Pending
- 2020-04-24 KR KR1020217038303A patent/KR20220005039A/ko not_active Ceased
- 2020-04-24 TW TW109113821A patent/TW202106662A/zh unknown
- 2020-04-24 CA CA3137956A patent/CA3137956A1/en active Pending
- 2020-04-24 EP EP20727876.3A patent/EP3959191A1/en active Pending
- 2020-04-24 US US17/605,780 patent/US20220402862A1/en not_active Abandoned
- 2020-04-24 AU AU2020261419A patent/AU2020261419B2/en active Active
- 2020-04-24 KR KR1020257033036A patent/KR20250152113A/ko active Pending
- 2020-04-24 MX MX2021012934A patent/MX2021012934A/es unknown
- 2020-04-24 SG SG11202111154WA patent/SG11202111154WA/en unknown
- 2020-04-24 PH PH1/2021/500045A patent/PH12021500045A1/en unknown
- 2020-04-24 JP JP2021562974A patent/JP2022530043A/ja active Pending
-
2021
- 2021-10-20 IL IL287421A patent/IL287421A/en unknown
- 2021-11-03 CO CONC2021/0014831A patent/CO2021014831A2/es unknown
-
2025
- 2025-01-23 JP JP2025009633A patent/JP2025066792A/ja active Pending
-
2026
- 2026-04-29 AU AU2026203197A patent/AU2026203197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012934A (es) | 2022-04-06 |
| JP2025066792A (ja) | 2025-04-23 |
| IL287421A (en) | 2021-12-01 |
| KR20250152113A (ko) | 2025-10-22 |
| BR112021021313A2 (pt) | 2022-01-18 |
| CO2021014831A2 (es) | 2022-01-17 |
| TW202106662A (zh) | 2021-02-16 |
| US20220402862A1 (en) | 2022-12-22 |
| EP3959191A1 (en) | 2022-03-02 |
| CN114127044A (zh) | 2022-03-01 |
| AU2026203197A1 (en) | 2026-05-14 |
| CA3137956A1 (en) | 2020-10-29 |
| NZ781026A (en) | 2025-07-25 |
| WO2020219876A1 (en) | 2020-10-29 |
| KR20220005039A (ko) | 2022-01-12 |
| AU2020261419B2 (en) | 2026-01-29 |
| PH12021500045A1 (en) | 2023-01-23 |
| JP2022530043A (ja) | 2022-06-27 |
| AU2020261419A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020261419B2 (en) | Ionizable amine lipids and lipid nanoparticles | |
| JP7485659B2 (ja) | イオン化可能なアミン脂質 | |
| US20250074866A1 (en) | Modified amine lipids | |
| AU2022210316A1 (en) | Nanomaterials comprising a biodegradable feature | |
| HK40069512A (en) | Ionizable amine lipids and lipid nanoparticles | |
| BR122024020580A2 (pt) | Compostos de amina ionizáveis, composição de nanopartículas de lipídeo que compreende os ditos compostos, uso da mesma e métodos in vitro para edição gênica e clivagem de um dna | |
| EA045069B1 (ru) | Ионизируемые аминолипиды | |
| HK40053394A (en) | Ionizable amine lipids | |
| HK40056304A (en) | Modified amine lipids | |
| BR122024007324A2 (pt) | Composto de lipídeos de amina modificados, composição de nanopartículas lipídicas (lnp) compreendendo o dito composto, usos da mesma e métodos para editar genes | |
| EA046244B1 (ru) | Модифицированные аминовые липиды |